VIA EDGAR

October 4, 2022

Office of Life Sciences

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jordan Nimitz

Acceleration Request for Registration Statement on Form S-1

File No. 333-267730

Requested Date:                October 6, 2022

Requested Time:                4:00 p.m. Eastern Standard Time

Dear Mr. Nimitz:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Amylyx Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to October 6, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Meg Dennard at (212) 813-8927. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Meg Dennard, by email to MDennard@goodwinlaw.com or by facsimile to (212) 202-4529.

[Remainder of page left intentionally blank]

If you have any questions regarding this request, please contact Meg Dennard of Goodwin Procter LLP at (212) 813-8927.

Justin B. Klee, Co-Chief Executive Officer, Amylyx Pharmaceuticals, Inc.

James M. Frates, Chief Financial Officer, Amylyx Pharmaceuticals, Inc.

Benjamin K. Marsh, Esq., Goodwin Procter LLP

[Signature Page to Acceleration Request]